EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise
Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.
You may also be interested in...
Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.
Patients with severe secondary mitral regurgitation treated with MitraClip and medical therapy have the same rate of death or unplanned hospitalization for heart failure at one year as patients treated with medical therapy alone, results of MITRA-FR show. Abbott, as well as other companies developing transcatheter mitral-repair technology, will now look to the COAPT trial to establish MitraClip's benefits on clinical outcomes.
Abbott Labs is jumping on the transcatheter mitral valve replacement (TMVR) bandwagon with an agreement to buy out the rest of Tendyne Holdings and an option to Cephea Valve Technologies, both announced July 30.